Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Downgrading of regulation in regenerative medicine.

Sipp D, Sleeboom-Faulkner M.

Science. 2019 Aug 16;365(6454):644-646. doi: 10.1126/science.aax6184. No abstract available.

PMID:
31416952
2.

Heritable Genome Editing in a Global Context: National and International Policy Challenges.

Rosemann A, Balen A, Nerlich B, Hauskeller C, Sleeboom-Faulkner M, Hartley S, Zhang X, Lee N.

Hastings Cent Rep. 2019 May;49(3):30-42. doi: 10.1002/hast.1006.

3.

Regulatory brokerage: Competitive advantage and regulation in the field of regenerative medicine.

Sleeboom-Faulkner M.

Soc Stud Sci. 2019 Jun;49(3):355-380. doi: 10.1177/0306312719850628.

4.

Genomics and genetic medicine: pathways to global health?

Gibbon S, Kilshaw S, Sleeboom-Faulkner M.

Anthropol Med. 2018 Apr;25(1):1-10. doi: 10.1080/13648470.2017.1398816. No abstract available.

PMID:
29533095
5.

The justification of studies in genetic epidemiology - political scaling in China Medical City.

Sleeboom-Faulkner M.

Anthropol Med. 2018 Apr;25(1):102-120. doi: 10.1080/13648470.2017.1381229.

PMID:
29533093
6.

Marketing of unproven stem cell-based interventions: A call to action.

Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, van Zimmeren E, Zarzeczny A, Rasko JEJ.

Sci Transl Med. 2017 Jul 5;9(397). pii: eaag0426. doi: 10.1126/scitranslmed.aag0426. Review.

7.

"(East) Asia" as a Platform for Debate: Grouping and Bioethics.

Sleeboom-Faulkner M.

Kennedy Inst Ethics J. 2016;26(3):277-301.

PMID:
27818393
8.

Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations.

Rosemann A, Bortz G, Vasen F, Sleeboom-Faulkner M.

Regen Med. 2016 Oct;11(7):647-57. doi: 10.2217/rme-2016-0072. Epub 2016 Sep 13.

PMID:
27622527
9.

Comparing national home-keeping and the regulation of translational stem cell applications: An international perspective.

Sleeboom-Faulkner M, Chekar CK, Faulkner A, Heitmeyer C, Marouda M, Rosemann A, Chaisinthop N, Chang HC, Ely A, Kato M, Patra PK, Su Y, Sui S, Suzuki W, Zhang X.

Soc Sci Med. 2016 Mar;153:240-9. doi: 10.1016/j.socscimed.2016.01.047. Epub 2016 Feb 2.

10.

New regulation for clinical stem cell research in China: expected impact and challenges for implementation.

Rosemann A, Sleeboom-Faulkner M.

Regen Med. 2016 Jan;11(1):5-9. doi: 10.2217/rme.15.80. Epub 2015 Dec 18. No abstract available.

11.

Translating 'Asian' Modes of Healing and Biomedicine.

Sleeboom-Faulkner M.

Med Anthropol. 2015;34(6):572-85. doi: 10.1080/01459740.2015.1092442. Epub 2015 Sep 21.

PMID:
26391564
12.

From global bioethics to ethical governance of biomedical research collaborations.

Wahlberg A, Rehmann-Sutter C, Sleeboom-Faulkner M, Lu G, Döring O, Cong Y, Laska-Formejster A, He J, Chen H, Gottweis H, Rose N.

Soc Sci Med. 2013 Dec;98:293-300. doi: 10.1016/j.socscimed.2013.03.041. Epub 2013 Apr 3.

PMID:
23623168
13.

Experimental treatments: Regulating stem-cell therapies worldwide.

Sleeboom-Faulkner M.

Nature. 2013 Mar 7;495(7439):47. doi: 10.1038/495047b. No abstract available.

PMID:
23467160
14.
15.

Experimental stem cell therapy: biohierarchies and bionetworking in Japan and India.

Sleeboom-Faulkner M, Patra PK.

Soc Stud Sci. 2011 Oct;41(5):645-66.

PMID:
22164719
16.

Dichotomies of collectivism and individualism in bioethics: Selective abortion debates and issues of self-determination in Japan and 'the West'.

Kato M, Sleeboom-Faulkner M.

Soc Sci Med. 2011 Aug;73(4):507-514. doi: 10.1016/j.socscimed.2011.05.053. Epub 2011 Jul 12.

PMID:
21803467
17.

Tensions between medical professionals and patients in mainland China.

Zhang X, Sleeboom-Faulkner M.

Camb Q Healthc Ethics. 2011 Jul;20(3):458-65. doi: 10.1017/S0963180111000144.

PMID:
21676333
18.

Meanings of the embryo in Japan: narratives of IVF experience and embryo ownership.

Kato M, Sleeboom-Faulkner M.

Sociol Health Illn. 2011 Mar;33(3):434-47. doi: 10.1111/j.1467-9566.2010.01282.x. Epub 2011 Jan 12.

19.

Genetic testing, governance, and the family in the People's Republic of China.

Sleeboom-Faulkner ME.

Soc Sci Med. 2011 Jun;72(11):1802-9. doi: 10.1016/j.socscimed.2010.03.052. Epub 2010 May 12.

PMID:
20627498
20.

Contested embryonic culture in Japan--public discussion, and human embryonic stem cell research in an aging welfare society.

Sleeboom-Faulkner M.

Med Anthropol. 2010 Jan;29(1):44-70. doi: 10.1080/01459740903304256.

PMID:
20391158
21.

Quality of offspring-The impact of new reproductive technologies in Asia. Editorial introduction.

Sleeboom-Faulkner M.

Cult Health Sex. 2010 Feb;12(2):137. doi: 10.1080/13691050903229997. No abstract available.

PMID:
19813119
22.

Bionetworking: experimental stem cell therapy and patient recruitment in India.

Patra PK, Sleeboom-Faulkner M.

Anthropol Med. 2009 Aug 1;16(2):147-63. doi: 10.1080/13648470902940689.

PMID:
27276407
23.

Choosing offspring: prenatal genetic testing for thalassaemia and the production of a 'saviour sibling' in China.

Sui S, Sleeboom-Faulkner M.

Cult Health Sex. 2010 Feb;12(2):167-75. doi: 10.1080/13691050902914110.

PMID:
19499399
24.

Reproductive technologies and the quality of offspring in Asia: reproductive pioneering and moral pragmatism?

Sleeboom-Faulkner M.

Cult Health Sex. 2010 Feb;12(2):139-52. doi: 10.1080/13691050902912767.

PMID:
19499397
25.

Chinese concepts of euthanasia and health care.

Sleeboom-Faulkner M.

Bioethics. 2006 Aug;20(4):203-12.

PMID:
17044154

Supplemental Content

Loading ...
Support Center